Endometriosis through an immunological lens: a pathophysiology based in immune dysregulation

Alison McCallion ☉, Danielle J. Sisnett ☉, Katherine B. Zutautas ☉, Donya Hayati ☉, Katherine G. Spiess ☉, Stanimira Aleksieva ☉, Harshavardhan Lingegowda ☉, Madhuri Koti ☉, Chandrakant Tayade* ☉

Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada

*Correspondence: Chandrakant Tayade, Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada. tayadec@queensu.ca

Academic Editor: Satish Kumar Gupta, Indian Council of Medical Research, India

Received: November 8, 2021 Accepted: March 8, 2022 Published: July 26, 2022

Cite this article: McCallion A, Sisnett DJ, Zutautas KB, Hayati D, Spiess KG, Aleksieva S, et al. Endometriosis through an immunological lens: a pathophysiology based in immune dysregulation. Explor Immunol. 2022;2:454–83. https://doi.org/10.37349/ei.2022.00062

Abstract

Endometriosis (EMS) is an inflammatory, gynaecologic disease characterized by the growth of endometrial tissues outside the uterus. With no satisfactory therapies or non-invasive diagnostics available, a shift in perspectives on EMS pathophysiology is overdue. The implication of immune dysregulation in EMS pathogenesis and disease progression has been an evolving area of research, with numerous immune and inflammatory pathways identified. Traditional theories regarding the establishment of endometriotic lesions have lacked mechanistic explanations for their proliferation and survival until recent research unearthed the involvement of mesenchymal stem cell (MSC) and myeloid-derived suppressor cells (MDSCs) in a complex network of immune-endocrine signaling. The unique immunology of EMS is likely owing to estrogen dominance, as endocrine imbalance reliably cultivates immune dysregulation. Many of the phenomena observed in EMS parallel immune biology seen in various cancers, including accelerated somatic mutations in endometrial epithelial cells. Here, the high mutational load leads to EMS neoantigen development which potentially contributes to the lesion immune microenvironment. As well, EMS manifests comorbidity with several chronic inflammatory diseases that share common dysregulation of the interleukin-23 (IL-23)/IL-17 pathway (as seen in inflammatory bowel disease, psoriasis, and rheumatoid arthritis). EMS is especially relevant to the study of chronic pelvic pain (CPP) as 60% of EMS patients experience this symptom and chronic inflammation is believed to be central to the process of pain sensitization. Since the onset of the disease usually occurs in adolescence, and diagnosis only occurs years later once moderate to severe symptoms have developed, it is vital to innovate non-invasive diagnostic tools for earlier detection. Several potential biomarkers are being studied, including some cytokines, gene signatures, and extracellular vesicle (EV) signatures. By incorporating the immune perspectives of EMS into our research, approaches to diagnosis, and treatment solutions, the field has more promising avenues to clearly define EMS and offer patients relief.
Keywords
Endometriosis, immune dysregulation, mesenchymal stem cells, somatic mutation, estrogen dominance, chronic inflammation, cytokine pathways, extracellular vesicles

Introduction
Endometriosis (EMS) is an inflammatory gynaecologic disease that affects about 10% of menstruating individuals worldwide. It is characterized by the growth of endometrial-like tissue at ectopic sites outside of the uterus; lesions most commonly being found on the peritoneal wall, exterior of uterus, ovary, bladder, or colon. In Canada alone, EMS is estimated to cost the healthcare system $1.8 billion annually [1]. The disease causes severe pelvic pain and infertility, and we do not have reliable non-invasive diagnostics or curative therapeutic options. To compound this difficulty, the average time between the onset of symptoms and diagnosis is approximately seven years. This is partially owing to the fact that the pathogenesis and pathophysiology of EMS are poorly understood. Aside from being under-studied, EMS is a multifaceted disease with etiologies rooted in genetics, hormonal imbalance, immune dysregulation, and phenotypic heterogeneity. Though years of research have unraveled individual contributions of these aspects, the mechanisms of their interplay remain largely elusive.

Because EMS is an estrogen-dominant disease, most first-line treatments attempt to address this imbalance through hormonal contraceptive therapies. These options do not cause regression of existing lesions, and contraception is not a satisfactory option for those who wish to conceive children. In recent years the field has acknowledged several immune cells and pathways that are dysregulated in EMS, contributing to severe inflammation, fibrosis, and angiogenesis in lesions. For this reason, immune-focused therapies with proven success in other chronic inflammatory diseases and several cancers are being explored in EMS. However, precise understanding of the complex immune-regulatory pathways is integral to the future application of immune-based therapeutics. Additionally, with high incidence of comorbidities and individual mutational variations, personalized medicine for EMS is an area needing significant research and development.

Despite these challenges, the field continually makes new discoveries in an immunological scope to understand EMS pathophysiology. The complexity of immune dysregulation in EMS is an active area of ongoing research, driving a forward deeper understanding of EMS pathophysiology and allowing us to attempt new approaches to diagnosis and treatment. In this article, we summarize current knowledge within a broader immune context and discuss areas of promising investigations with perspectives on diagnostics and treatments.

Theories of endometriosis lesion establishment
Several theories exist to explain the presence of EMS lesions, and while their applicability varies across disease phenotypes, each has its own merit. Familial associations have been documented for EMS [2–4] and have been reviewed elsewhere [5–8]. A pioneer of EMS pathogenesis research was John Sampson, and his works have been discussed extensively by Yovich et al. [9]. The widely accepted Sampson’s theory of retrograde menstruation, in our opinion, is most feasible as a part of a larger story which includes immune dysregulation and aberrant stem cell activity as discussed below.

Coelomic metaplasia
This theory postulates that metaplasia and transdifferentiation occur in the mesothelium of the peritoneum and within the ovarian germinal epithelium, thereby transforming these cells into endometrial tissue that can cause lesion development [10]. This hypothesis may explain rare cases of EMS seen in males [11, 12]. Metaplasia could also explain rare distal EMS lesion sites such as lymph nodes [10] and lungs [13]. Some have theorized that the presence of deep infiltrating EMS (DIE) is caused by metaplasia of the coelomic epithelium, however, there is a high prevalence of rectovaginal DIE that co-occurs with other forms of EMS, where coelomic metaplasia cannot explain lesion presence [14]. Metaplasia can also arise from events unrelated to
the coelomic epithelium, or from ectopic tissue implanting into peritoneal sites [15]. These theories can be applied to certain phenotypes of EMS, however, they do not account for the prevalent immune dysregulation seen in the disease pathophysiology.

**Mullerian remnant theory**

The Mullerian ducts, which normally differentiate to form the female reproductive tract, are said to be involved in this etiological hypothesis of EMS. The ectopic endometrial tissue that is characteristic of EMS is theorized to originate from primitive embryonic Mullerian tissue that was misplaced during fetal development [16, 17].

Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, caused by an anomaly in the Mullerian tract, is characterized by abnormalities or absence of the uterus and vagina, despite the normal function of ovaries and (46,XX) karyotype. MRKH patients have been shown to have a significant incidence of EMS, bolstering this hypothesis [18]. There has also been EMS documented in individuals with Mullerian anomalies, despite no obstruction in menstrual flow [19]. Additionally, cases of EMS in girls before menarche [20], as well as males with lesions along the route of the Mullerian duct, align with this hypothesis [11]. However, this theory is not sufficient for explaining the placement of lesions seen outside of Mullerian rests [12], or the immunological aspects of EMS.

**Iatrogenic scar endometriosis**

Iatrogenic endometriotic growths typical of EMS can develop within incision scars from gynecologic surgery [21]. Specifically, iatrogenic scar EMS is suggested to arise from accidental auto-transplantation of endometrial cells [22–24]. Lesions may be found in incisions from cesarian, appendectomy [22], hysterotomy, tubal, trocar-site, amniocentesis, and episiotomy surgeries [25, 26]. This hypothesis explains rare cases of EMS development in those who have recently undergone pelvic surgery. Endometrial cells being transplanted into incision sites is a reality of the cesarian section, yet the occurrence of EMS in the scar is quite low, indicating other unidentified factors lead to disease development in these cases [22]. Immune tolerance during pregnancy in combination with the displacement of endometrial cells is a reasonable speculation for the etiology of lesion establishment in cases of cesarian section surgery [26]. This is evidenced by the increased risk of scar EMS for those who deliver prior to labor onset before immune tolerance has subsided [27].

**Retrograde menstruation**

Retrograde menstruation, originally proposed by Sampson [28], is currently the most widely-accepted hypothesis for the etiology of EMS. This hypothesis postulates that endometrial fragments shed during menstruation travel backward through the fallopian tubes into the peritoneal cavity, where cells can adhere and develop into endometriotic lesions.

Retrograde menstruation has been well established as a normal physiological process, occurring in 90% of menstruating individuals [29]. Some non-human primates like baboons, who also menstruate, have exhibited cases of spontaneous EMS associated with a higher prevalence of retrograde menstruation [30]. Also in baboon models, forced menstrual reflux by cervical occlusion has been shown to induce EMS [31]. Similarly, EMS and retrograde menstruation have been shown to be increased in individuals with outflow obstruction, such as those with malformation of Mullerian ducts [19]. There is also a positive association between EMS and high menstrual volume (typical of heavy periods or greater numbers of menstrual cycles) [32]. Additionally, differences in endometrial tissue adhesion capability have been identified in patients with EMS; adhesion molecules such as integrins, syndecans, cluster of differentiation 44 (CD44), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and epithelial cadherin (E-cadherin) can be dysregulated in EMS patients, explaining the increased capacity to adhere to damaged peritoneum [12, 33].

While 90% of females exhibit retrograde menstruation, only 7–10% are estimated to have EMS [34], meaning that other factors must contribute to disease establishment. For lesion establishment to occur from displaced endometrial cells, there must be immune evasion, attachment, invasion, vascularization, and growth. Although endometrial fragments are misplaced at ectopic sites, the adaptive immune system may
not mount an effective response to clear debris due to the recognition of endometrial cells as self-versus foreign antigens. Several pathways of immune dysfunction have been identified in EMS that could contribute to lesion establishment. For instance, macrophages (normally recruited for tissue repair and debris clearance) have been shown to produce increased amounts of vascular endothelial growth factor (VEGF) in EMS patients compared to controls [35]. This increase in VEGF, an angiogenic factor, could be supporting the vascularization of the lesion. Another mechanism previously described is estrogen receptor β (ERβ) interacting with apoptotic machinery to decrease tumor necrosis factor-alpha (TNF-α)-mediated apoptosis, proposed as a mechanism by which displaced cells evade immune clearance [36]. Many other mechanisms in addition to immune dysfunction can complicate the pathophysiology of the disease, such as genetic, environmental, and endocrine factors. While retrograde menstruation is a plausible theory explaining the presence of endometrial cells in the peritoneal cavity, more recent discoveries relating to stem cells and immune pathways have allowed us to theorize how immunological factors lead to EMS after endometrial cells enter the peritoneal cavity.

**Stem cell theory**

Somatic stem cells, also known as adult or tissue-specific stem cells, play a critical role in the regulation of adult tissue regeneration and restoration of the local microenvironment following injury [37]. The human endometrium is a dynamic tissue that undergoes cyclic regeneration through the replacement of epithelial and mesenchymal tissue following menses. A growing body of evidence suggests endometrial epithelial stem/progenitor cells are involved in the repair process, along with CD140b+CD146+ or sushi domain containing-2+ (SUSD2+) endometrial mesenchymal stem cells (MSCs), and endometrial stem cells that may be of Mullerian origin [38]. Additionally, non-resident bone marrow-derived stem cells (BMDSCs), which differentiate into populations of hematopoietic stem cells, MSCs, and progenitor cells may be involved. It is possible that these cells restore endometrial tissue. Du et al. [39] found murine uteri with reperfusion injury harbored nearly twice as many BMDSC-derived MSCs compared to uninjured uteri (42 versus 22 MSCs per 10^5 stromal cells). As well, BMDSCs have been shown to differentiate into non-hematopoietic lineages including kidney, intestine, lung, and muscle cells [40]. Pathogenic alteration of stem cell regulation, function, number, and location provides a basis for lesion establishment in EMS.

The MSC theory of EMS purports that endogenous endometrial stem/progenitor cells, predominantly located in the endometrium basalis, travel in the menstrual fluid to reach the peritoneum and incorporate within lesions. Several researchers have noted the presence of basalis-like tissue in the menstrual effluent and endometrium functionalis of endometriosis patients [41, 42]. As well, some have theorized a deeper plane of separation between functionalis and basalis at menstruation, theoretically including more basalis-associated progenitor cells within the menstrual effluent of endometriosis patients [43]. In the context of retrograde menstruation, this would effectively boost the progenitive capacity of menstrual effluent in endometriosis patients as proportionally more progenitor/stem cells are transported to the peritoneal cavity. One school of thought hinges on the concept that decidualization primes endometrial stromal cells to recruit MSCs and prioritize tissue remodeling as part of normal endometrium restoration after menstrual shedding [44]. It is possible that with increased or dysregulated MSCs, endometrial stromal cells herd MSCs to ectopic sites where lesion establishment occurs. In the presence of an existing lesion, local dysregulation of cytokines, such as elevated C-C motif chemokine ligand 2 (CCL2), CCL5, C-X-C motif chemokine ligand 8 (CXCL8), VEGF, and placental growth factor [45–48], contribute to an inflammatory microenvironment that may recruit stem cells to the lesion site.

The involvement of MSCs is not limited to scaffolding lesion establishment. The cells exhibit immunomodulatory properties that inhibit proliferation, activation, and differentiation of CD4+ T cells to pro-inflammatory T helper (Th) Th1 and Th17 subtypes and promote the generation of tolerogenic regulatory T (Treg) cells [49]. In addition, tissue-resident MSCs have shown the capacity to modulate the activity of natural killer (NK) cells in a manner that reduces cytotoxicity and provides feedback that positively influences the proliferative and pro-angiogenic properties of MSCs. Reduced cytotoxicity of NK cells is also well documented in EMS [50]. MSCs have been shown to polarize macrophages to the M2 phenotype through
the release of prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase 1 (IDO1), CCL2, and CXCL12 [51–54]. In fact, MSCs have been found to exhibit more immunosuppressive and M2-polarizing signals in vitro when derived from EMS lesions compared to eutopic endometrium derived MSCs, which Abomaray et al. [55] theorized aids immune evasion to support lesion establishment. The secretory profile of MSCs includes chemoattractant cytokines that further MSC recruitment (CXCL12, CCL2, CXCL8) as well as antiapoptotic [insulin-like growth factor-1 (IGF-1), transforming growth factor beta (TGF-β), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF)], proliferative [interleukin-6 (IL-6), stromal cell-derived factor-1 (SDF-1), macrophage colony-stimulating factor (M-CSF)], and angiogenic [VEGF, placental growth factor (PIGF), monocyte chemoattractant protein-1 (MCP-1), bFGF] chemokines [56]. Overall, the breadth of interactions induced by MSCs appears to promote an immunosuppressive environment, permissive to the establishment and sustainment of ectopic tissue/lesions within the peritoneal cavity.

The presence of stem/progenitor cells of BMDSC origin may be associated with disease pathogenesis, as these cells have been shown to migrate to areas of tissue damage and inflammation. A study by Sakr et al. [57] showed that CD45− donor BMDSCs favored engrafting endometriotic lesions over eutopic endometrium in EMS-induced mice following bone marrow transplantation. This evidence supports the involvement of circulating BMDSCs in endometriotic lesion establishment. Furthermore, BMDSCs could regulate the formation and maintenance of blood vessels through their supply of myeloid cells, such as macrophages and mast cells, which release angiogenic factors including VEGF, TNF-α, and angiopoietin [38, 58]. Neoangiogenesis is a key feature in EMS lesion establishment and survival.

Chen et al. [59] found endometrial stromal cells interact with BMDCs to induce them to differentiate into stromal, epithelial, or leukocyte cell types via paracrine activity. BMDCs inhibit lymphocyte immune responses through increased expression of programmed cell death 1 (PD-1) and its ligand PD-L1 expression on T cells. Indeed, elevated serum PD-1/PD-L1 expression was observed in eutopic and ectopic endometria, as well as serum-derived CD4+/CD8+ T cells in patients with versus without EMS, the occurrence of which is reported to be exacerbated by elevated estradiol [60]. The chemotactic capacity of BMDSCs is specially enhanced with elevated CXCL12 levels, as is seen in EMS lesions [61]. In a mouse model of EMS, elevated CXCL12 has been shown to support the recruitment of bone marrow cells, a source of endothelial progenitor cells, to allow for neovascularization of EMS lesions [61, 62].

Myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid progenitor cells with potent immunosuppressive and angiogenic activity. Several studies have noted an association between MDSC accumulation and the progression of inflammatory diseases, including EMS [63–66]. MDSCs are present in small numbers in healthy tissue, although they rapidly expand in response to inflammatory disease through interactions with molecules such as IL-1β, IL-6, IL-10, and TNF-α [65, 67]. Elevated concentrations of these inflammatory cytokines in the peritoneal fluid (PF) of EMS patients may also be implicated in the transformation of monocytes into MDSCs [68–70]. The presence of chemokines CXCL1, CXCL2, and CXCL5 at the site of the lesion promotes MDSC migration to the ectopic environment [63]. Furthermore, Guo et al. [71] observed significantly elevated concentrations of CCL3 and CCL5 in EMS patients, cytokines associated with recruitment of MDSCs. Alongside this effect, recruited MDSCs may further secrete C-X-C motif chemokine receptor 2 (CXCR2), which has been associated with interferon-γ (IFN-γ)-induced upregulation of immunosuppressive molecules (e.g., PD-1, PD-L1) and monocyte recruitment (CXCL5, CCL3) that promote exhaustion of CD4+ and CD8+ T cells [66]. The presence of CXCR2+ MDSCs may further enhance the production of IL-6, which is implicated in lesion establishment through the promotion of epithelial-mesenchymal transition, a pathogenetic mechanism whereby endometrial cells transition from an epithelial phenotype to a more motile and invasive mesenchymal phenotype [72]. Chen et al. [64] associated the presence of elevated levels of monocytic-MDSCs (M-MDSCs) in peripheral blood and PF of EMS patients with suppressed pro-inflammatory Th and cytotoxic T cells in peripheral blood and enhanced anti-inflammatory Treg cells in the PF compared to healthy controls.

Thus, the recruitment and accumulation of excess MDSCs in the ectopic environment may be responsible for the protection and promotion of endometriotic implants in the peritoneal cavity. In addition, Chen et al. [64]
detected the presence of elevated M-MDSCs was further associated with an increase in the production of reactive oxygen species (ROS), possibly via the Notch signaling pathway [64, 73]. Findings by Ngô et al. [74] propose the involvement of ROS in increasing the proliferative rate of stromal and epithelial cells, both of which contribute a large proportion of the lesion's composition.

MDSCs further contribute to the development of EMS through cell-to-cell interactions. Morales et al. [75] have described the capacity of MDSCs to enhance the inflammatory responses of mast cells. As well, mast cells release chemoattractants to increase MDSC recruitment and expansion, predominantly through the promotion of CCL2 secretion and elevated IL-17 production [76–78]. Within lesions, mast cells may further interact with endometrial cells to secrete CCL8, which promotes endometrial cell migration and angiogenesis at the site of release, and may further upregulate pro-inflammatory factors such as IL-6, IL-10, IL-13, TNF-α, and VEGF [79, 80].

The involvement of MSCs and MDSCs in EMS lesion establishment is a promising hypothesis with strong evidence. The findings to date are congruent with a story of EMS pathogenesis where dysregulated immune signaling bridges the gap between retrograde menstruation and lesion establishment.

Prevalent relationships of endocrine and immune systems in endometriosis pathophysiology

EMS has long been considered an endocrinological disease. With recent research identifying significant immune dysregulation in the disease pathophysiology, we must consider the relationships between endocrine and immune systems. As EMS is an estrogen-dependent disease, hormonal therapies are the first-line treatments offered to patients, including combined estrogen and progesterone contraceptives, synthetic androgens, and gonadotrophin-releasing hormone (GnRH) agonists [81–83]. These therapies do not stop the progression of lesion growth and in many cases fail to provide patients with pain relief [84]. Estrogen has a complex role in immune functions as it can activate pro- and anti-inflammatory pathways in different cell types at different cycle points [85–87]. All immune cells express receptors for estrogen (ERα, ERβ) [86] while several express progesterone receptors (PRs), and respond to hormonal stimulation by altering inflammatory behavior, differentiating, or activating, depending on the cell and signal [88–94]. Several immune cell populations are pertinent in EMS immunopathophysiology; including but not limited to mast cells, macrophages, and various types of T cells, which are all affected by estrogen dominance.

Estrogen and progesterone can activate ERs and PRs as transcriptional factors, but also as non-genomic membrane receptors to rapidly activate cellular responses in leukocytes [95–97]. Hormonal stimulation also alters the immune signaling of the endometrium. High estrogen induces endometriotic epithelial and stromal cells to secrete more inflammatory and chemokine factors, including CCL5, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, IL-8, and CXCL12 [98–100]. Since endometriotic lesion tissue overexpresses aromatase (CYP19), estradiol is biosynthesized in high amounts [101]. Combining this with impaired local metabolic enzyme activity, including poor conversion of 17β-estradiol to estrone by 17β-hydroxysteroid dehydrogenases (17β-HSD) [102], the lesion hormonally contributes to its own local inflammatory microenvironment.

Endocrine and immune systems work closely together in the menstrual cycle, and menstruation is a highly immunologically active process. It is known that most immune cells are hormonally regulated and their presence in endometrial tissue follows a cyclic fluctuation according to the menstrual cycle, with an increase in abundance of macrophages, mast cells, neutrophils, NK cells, and Th1 cells at day 26–28 [90, 103–105]. The systemic hormonal imbalance in EMS manifests as both abnormally high estrogen and also the development of progesterone resistance; a lack of response to progesterone by endometriotic tissue. In the normal endometrium, progesterone regulates appropriate apoptosis and counteracts epithelial proliferation induced by estrogen. Receptors for estrogen (ERα, ERβ) and progesterone (PR-A, PR-B) are expressed abnormally in endometriotic tissue; lesions express more ERβ and less ERα than healthy endometrium, and generally low transcript levels of PR mRNA [106, 107]. With the absence of PRs in endometrial stromal cells, normal progesterone-stimulated production of the enzyme 17β-HSD-2 is disabled, hindering estradiol
metabolism and further maintaining a high estrogen level [108]. This is compounded by estradiol production resulting from aromatase activity in endometriotic tissue, as CYP19 expression is significantly increased in endometriosis lesions compared to healthy endometrium [109, 110].

Several immunological alterations are associated with supraphysiological estrogen. For example, high estrogen is associated with a systemic increase in G-CSF as granulocytes are important in the process of ovulation [111]. Normally progesterone rescues this effect, but in the progesterone-resistant state of EMS, estrogen may contribute to chronic leukocyte colony stimulation (Figure 1A). Likewise, other immune impacts of progesterone are relevant in EMS, where inflammatory events normally rescued by progesterone are left unregulated. Progesterone inhibits chemokine secretion by stromal cells [100], opposing estrogen's agonistic effect on chemokine secretion in stromal cells (Figure 1B). Progesterone also inhibits mast cell migration [112], secretion and histamine release [113]. Mast cells fluctuate cyclically and are actively involved in the menstruation process [114, 115], and it is known that mast cells can mature and activate upon estrogenic stimulation [95]. Mast cells have been found in higher quantities in the tissue of endometriotic lesions compared to eutopic endometrium and the endometrium of healthy women [116, 117]. In addition, the vital mast SCF has been observed in higher concentrations in women with EMS [118].

![Figure 1. The immune-endocrine relationships of the endometriotic lesion. (A) Estradiol is sourced from systemic circulation and, to a small extent, the lesion tissue itself. Estrogen acts on immune cells to secrete inflammatory, angiogenic, chemokinetic molecules which contribute to lesion growth and disease progression; (B) estradiol causes the endometriotic lesion to produce immune signaling molecules [CCL5, GM-CSF, IL-6, IL-8, CXCL12, VEGF, stem cell factor (SCF)], subsequently acting on local immune cells to further increase inflammation, angiogenesis, and proliferation of the lesion](https://doi.org/10.37349/ei.2022.00062)

EMS patients have a significantly higher number of endometrial and peritoneal macrophages as compared to healthy women during the proliferative phase, and other reports found significantly higher macrophages in EMS patients regardless of menstrual phase [119, 120]. Macrophages polarize into either M1 or M2 phenotype, which have distinguished cytokine profiles and downstream actions. Generally, the M1 phenotype is pro-inflammatory, it is the classically activated macrophage that scavenges and launches immune responses to infections [121]. Meanwhile, M2 macrophages are alternatively activated and have generally anti-inflammatory downstream effects [121, 122]. Studies of macrophages under estrogenic stimulation have observed polarization to the M2 phenotype, which is considered more permissive, and this may support ectopic endometriotic lesion proliferation by allowing decidualized endometrial cells to escape clearance and survive/proliferate at ectopic sites [123–126]. Macrophages from EMS patients were found to express much more ERβ, which induces more inflammatory secretions from macrophages such
as TNF, IL-1α, and IL-1β (Figure 1A) [119, 127, 128]. Since the immunomodulatory actions of estrogen are complex, other studies have found estradiol-induced polarization of macrophages to the M1 phenotype which performs inflammatory roles secreting cytokines like IL-6 and TNF-α, which may contribute to the increased inflammation of the EMS immune microenvironment [129]. Macrophages also contribute to pain symptoms in concert with estrogenic activation in EMS [87, 130]. These endocrine relationships require further investigation to improve our understanding of the roles of macrophages in EMS pathophysiology.

T cells have been identified for their role in various immunological pathways of EMS pathophysiology, and most T cell populations are influenced by estrogen [104]. Th cells exhibit an interesting relationship to estrogen and progesterone balance, where the pro-inflammatory Th1 population rises in the estrogen-dominant follicular phase while a Th2 population takes over in the luteal phase to contribute their immunoregulatory role, as observed by Faas et al. [91]. As well, estradiol has PD-1-dependent and -independent suppressive actions in the function of Treg cells (Figure 1A) [131]. Importantly, Mohammad et al. [132] elucidated the significance of ERα activation in the function, regulation, and survival of T cells by observing poor activation and survival of ERα-knockout T cells in a mouse model of colitis. A particularly interesting inflammatory pathway involving Th17 cells has been noted in EMS, and increased Th17 level in the PF of patients has been identified in association with disease severity [133]. Fuseini et al. [134] showed that ERα in Th17 cells increases the IL-23/IL-17 inflammatory pathway by upregulating IL-17A production. This inflammatory pathway has become increasingly relevant to our understanding of EMS pathophysiology, specifically relating to the recruitment of macrophages [135]. The involvement of estradiol and other endocrine factors is a significant aspect of T cell function and should be considered in researching EMS pathophysiology.

An important question to consider is whether the immune-endocrine relationship in EMS pathophysiology is bi-directional. It is known that hormones influence immune cell actions and immune signaling. However, a less observed relationship is the impact of immune events on sex hormone metabolism and receptor regulation. Some pathways in both normal and disease scenarios have been identified. In endometrial carcinoma, estrogen-stimulated IL-6 has been found to upregulate stromal cells’ expression of aromatase, driving forward metabolism of androgens to 17β-estradiol, resulting in a positive feedback loop of IL-6 and E2 production [136]. Both aromatase and IL-6 have roles identified in the pathophysiology of EMS [137], and given this feedback loop has been identified in other estrogen-dependent diseases, e.g., various breast cancers [138], this very feedback loop could exist in the disease. In several endocrine-dependent cancers, ERα can be activated by IL-1β and TNF-α via the IkappaB kinase-beta (IKK-β) pathway [139]. These cytokinic ER activation pathways are not well studied in EMS, though given the existing parallels between EMS and cancer, the capacity of immune signaling to activate sex steroid hormone receptors may be worth a deeper investigation.

Mutations and cancer parallels in endometriosis

Knowledge of the endometriotic microenvironment is continuously expanding with new information centered around angiogenesis, cytoarchitecture, etiology, and immune cell presence; the field is diversifying. These seemingly independent fields are all relevant to novel establishing tissues. This framework allows for parallels to be made to malignant cancerous tissues. This is not to equate EMS to cancer, but to provide an alternative perspective in analyzing endometriotic lesions through the lens of cancer research. The breadth of cancer research has made discoveries that could prove beneficial to the field of EMS research. As this school of thought has been gaining traction in the field, we hope to provide insight into the pathophysiology of EMS through this perspective. With a focus on somatic mutations and immune cell dysfunction, there may be insights into potential biomarkers and novel therapeutics for EMS.

Somatic mutations in endometriosis

Genomic studies in EMS patients typically aim to comment on disease etiology and heritability [140, 141]. One emerging topic is somatic mutations and their influence on EMS pathophysiology. Whole exome sequencing of EMS has revealed the presence of single nucleotide variations in ectopic and eutopic sites, with mutually exclusive mutations across these locations [142]. Alterations to genes supporting
cell adhesion, apoptosis, and cell cycle pathways have all been identified and maintain a heterogeneous presentation across patients. These pathways have similarities with known cancer driver mutations, allowing for proliferation and metastasis of tissues. Cancer driver mutations such as AT-rich interaction domain-containing protein 1A gene (ARID1A), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and Kirsten rat sarcoma virus proto-oncogene (KRAS) mutations have been found in the epithelium of EMS patients [143–145]. There is still a large debate over the role that these mutations play in the potential progression of EMS to endometrial cancers, however, even in non-cancerous lesions, such as those in DIE, these mutations are present [143]. The acquisition and interpretation of this data have been extensively reviewed elsewhere [140], however, one dimension of this discussion yet to be brought to EMS is the impact of somatic mutations on immune function. Cancer literature highlights the influence that somatic mutations can have on immune cell infiltration as well as cytotoxic capacity [146–149], thus calling us to discuss the effect of mutations in pathways beyond just the cytoarchitecture of the lesion itself.

Mutational load, the amount of somatic mutations present within a tissue, has been correlated with tumor leukocyte infiltration [146, 148, 149]. This in part could be due to the over-activation of the mutated signaling pathways having downstream targets that contribute to inflammation, such as IFN-γ and TGF-β [147, 150, 151], however, the formation of neoantigens is where the current focus lies. Neoantigens are proteins that have been modified due to mutations, and that present as novel targets for the immune system. With a higher mutational load, there is the potential for greater neoantigen formation and thus a greater capacity for mounting an immune response against these new targets (Figure 2) [146]. Across various cancers, there is an association with mutational load, neoantigen formation, tumor leukocyte infiltration, and the expansion of the T cell repertoire [148, 149]. Comparing the ratio of gene expression within T cells infiltrating these genetically different tissues, there is an increase in cytolytic capacity, as measured by granzyme A expression as well as an increase in Treg marker forkhead box p3 (Foxp3), potentially counterbalancing the immune cell clearance taking place [148]. Due to this heightened tumor leukocyte infiltration, the mutational load can be associated with better patient outcomes, however, this is very microenvironment specific, as the functional capacity of the infiltrating cells still needs to be considered. Additionally, the mutational landscape at each tumor or potentially lesion site has its own microenvironment. Within EMS, both intra- and inter-lesion heterogeneity of mutations has been identified, thus it is fair to assume that the neoantigens present will differ at all locations. This adds complexity, in that parallel immune interactions are taking place with specificity to their microenvironment. EMS literature has identified the presence of CD8+ T cells as well as an abundant immune infiltrate at the lesion site [152, 153]. Further research is needed however to elucidate these immune populations and to identify the functional status of these cells. This information would bring us one step closer to understanding the lesion’s complex network, of which somatic mutations are a part.

As previously mentioned, it is the epithelial cells within endometriotic lesions as well as tumors, that harbor the vast majority of somatic mutations [143–145, 154]. Stromal cells have been reported to have very few or no somatic mutations, however, they do carry epigenetic modifications [154–156]. This marked difference in mutation presence is explained by the relationship between these tissues and their contribution to the lesion/tumor site; epithelial cells are under the influence of stromal cells [150]. The epigenetic modifications of stromal cells cause alterations to their receptor expression and cytokine release [157]. Both mechanisms are exploited to promote the proliferation of epithelial cells, increasing their mutation acquisition. Within EMS this can manifest as increased ERβ, supporting proliferation by heightening the sensitivity to estrogen, PR downregulation contributing to progesterone resistance, and increased paracrine cytokine production of growth factors (HGF and TGF-β) targeted to the epithelium [150, 157]. Once combined, these signals increase the rate of epithelial proliferation and mutation. Advancing our understanding of this complex relationship will allow for a greater understanding of these inherent cell properties and how mutations fit in their physiology.

The study of somatic mutations within EMS is in its infancy. New findings continue to highlight the dynamic nature of these tissues, guiding us to adjust our perception of normal tissues and the role of cancer driver mutations. Lac et al. [158] identified that 50% of healthy endometrium contains cancer driver mutations and that acquisition will increase proportionally with age. Mutations are no longer relegated to the abnormal,
requiring us to adjust our perspective of “normal” tissues. We must seek to understand the pathways they exploit and the potential room for their influence at various stages of disease progression. Adding to this complexity is the presence of allelic variations in mutations, thus while the presence of one may influence tumor leukocyte infiltration and correlate with positive patient outcomes, another may not [147, 159]. The importance of individual microenvironments cannot be understated and will eventually be the focus in therapeutics, as immune-centered therapies continue to rise. Anti-PD-1/PD-L1 therapies in various cancers have looked to mutational load as an indicator of patient success with immunotherapies [146, 147, 160]. This underscores the need for understanding the status of immune cells present within the lesion and how they interact with these mutations to capitalize on those networks. Finally, more work is needed considering a place for neoantigens within EMS. The prevalence of these mutations in normal tissues may be preventing the immune system from mounting a response to those within endometriotic lesions as it does not recognize these as foreign. The selection process of T cells within the reproductive tract as well as the repertoire of these cells needs further research to understand at what point these mutations can be recognized as foreign and then cleared.

Figure 2. Lesion immune microenvironment and inflammatory cycle. (1) Inherent mutational predispositions differ across epithelial and stromal cells. Epi-genetic stromal cell alterations promote an environment that stimulates further replication and mutational acquisition within epithelial cells. (2) This increased presence of somatic mutations allows for the formation of neoantigens which are detected by antigen-presenting cells (APCs) and presented to adaptive immune cells. (3) The lymphocyte fate from these interactions is yet to be determined, forming a novel target of the investigation to define immune phenotype and activation status of T cells in response to lesion-specific neoantigens. (4) Phenotypic fate is not yet determined, but higher immune cell infiltration has been seen in lesions with increased somatic mutations. Elevated immune cell infiltration is a facet of another potentially dysregulated pathway within the lesion microenvironment. (5) IL-23, which is increased in EMS, is mainly secreted by APCs. (6) This cytokine is crucial for the expansion and stabilization of “pathogenic” Th17 cells resulting in high levels of IL-17, which has potent pro-inflammatory and pro-angiogenic actions in EMS. (7) IL-23 may also then promote the dysregulated ratio of Th17 and Treg cells seen in EMS derailing immune homeostasis. (8) As IL-17 receptor A (IL-17RA) is expressed on immune cells including T cells, IL-17 may promote Th17 cells to induce inflammation, recruit neutrophils, and further produce pro-inflammatory cytokines, supporting the establishment and maintenance of endometriotic lesions

The immunological basis of chronic pelvic pain

Chronic pelvic pain (CPP) is defined as non-menstrual pain originating from the pelvic region which typically persists for more than 6 months [161, 162]. CPP is estimated to affect 26% of the world’s female population, accounting for 40% of laparoscopies and 12% of hysterectomies annually in the US [162]. In regards to EMS, which is commonly characterized by debilitating CPP, more than 60% of all EMS patients report CPP [163]. In fact, of the 60% of laparoscopies performed for CPP of which an abnormality is identified, 85% of these
patients reveal early-stage EMS or adhesions [162]. Existing evidence indicates that CPP can frequently persist in EMS patients following successful lesion excision, despite a lack of lesion regeneration and/or the usage of hormonal therapies [163, 164]. Furthermore, it is well known that the number or spread of lesions, as classified by the American Society for Reproductive Medicine (ASRM) staging, is not indicative of one’s degree of pain [161, 165–167]. This supports the idea that EMS-related CPP is not entirely reliant on the presence or number of lesions and is likely driven by other factors. Moreover, due to the complexity of CPP symptomology, which is reviewed extensively elsewhere [162, 168], identifying the exact mechanism(s) of CPP is extremely challenging. However, several hypotheses have been proposed to be the cause of CPP, including immune dysfunction, neuropathies, and psychosocial modulators [162, 169].

The scope of CPP is broad, however, the aspect of immune dysfunction is a very understudied area. While the mechanistic link between CPP and EMS remains undefined, one of the avenues being explored is the link between CPP, EMS, and inflammation. There are various evidence that CPP results from a localized pro-inflammatory milieu containing upregulated Th cells, mast cells, and the secretion of inflammatory mediators [162, 169, 170]. EMS is characteristically known for its chronic inflammatory milieu [171]. This link is particularly of interest due to the well-documented immune-centered comorbidities in EMS and their role in CPP, as discussed elsewhere [169, 170, 172]. The dysregulated inflammation in CPP/EMS increases the infiltration of immune cells, such as mast cells, macrophages, and lymphocytes [169, 171, 173], which further amplifies inflammation in the microenvironment. Specifically, mast cells promote the infiltration of other inflammatory cells that further activate mast cells, creating a positive feedback loop of chronic inflammation [169]. Cytokines secreted by activated mast cells (IL-6, IL-21, IL-23, and TGF-β) are also known to regulate Th17/Treg cell differentiation and plasticity, suppressing Treg control of self-tolerance which is crucial to avoid immune dysfunction [169, 170]. Mast cells may play a key role in chronic pain and hyperalgesia in EMS due to their expression of nerve growth factor (NGF) receptors, as the downstream results of binding of NGF may result in a feedback mechanism which promotes pain sensitization [169]. Furthermore, due to the shared neural pathways innervating the bladder, colon, and female reproductive tract, this can lead to cross-organ sensitization and CPP [162, 163].

It is suggested that cross-talk between the nerves and immune cells/modulators within the chronic inflammatory milieu of EMS results in the activation of central and peripheral pain pathways, magnifies pain signals, and leads to CPP [162, 169–171, 173, 174]. Particularly, PGE2, TNF-α, NGF, CCL5, IL-8, and IL-1β are key inflammatory mediators increased within the endometriotic microenvironment which directly activate sensory nerve endings and create a positive feedback loop to further exacerbate inflammation [163]. In EMS, IL-1β specifically is known to stimulate NGF promoting local neurogenesis, and is associated with severe deep dyspareunia [175, 176].

It is also crucial to consider psychosocial modulators, such as trauma, abuse, and poor mental health as possible contributing factors for CPP. Women with CPP are significantly more likely to report experiencing physical/sexual/verbal/emotional abuse during childhood [162]. Although the cause-and-effect of this pain is difficult to decipher, it is speculated that these psychosocial modulators uniquely sensitize patients due to their experience of trauma, making them more vulnerable to developing CPP. As psychosocial health breaches the scope of this article, we encourage readers to review the literature on this topic [162, 177, 178]. Overall, it is clear that CPP has an extremely complex etiology. However, as there are growing reports of these key inflammatory mediators contributing to CPP, we must improve our understanding so as to utilize this novel information that will aid in defining disease pathophysiology and the development of an effective and non-invasive therapy avenue for EMS patients suffering from CPP.

Role for Th17 pathway in EMS lesion microenvironment

As previously mentioned, there are a few key immunological factors known to be increased in the PF of EMS patients, including IL-1β, IL-6, TGF-β1, IL-17, and VEGF [174, 179, 180]. These mediators greatly influence the microenvironment in EMS, driving neurogenesis and persistently bathing lesions in a pro-inflammatory and pro-angiogenic environment that is engineered to support lesion establishment and survival [161, 165, 171, 181]. Interestingly, IL-1β, IL-6, and TGF-β1 have been well-documented to be directly
involved in the differentiation of “pathogenic” Th17 cells, when in combination with IL-23 [182–185].
Specifically, TGF-β1, IL-1β, and IL-6 are known to promote Th17 cell differentiation from naive CD4+ T cells by
inducing a signal transducer and activator of transcription 3 (STAT3)-dependent expression of IL-21, IL-23R,
and retinoid-related orphan receptor γt (RORγt), a lineage-specific transcription factor required for Th17 cell
generation which promotes expression of genes IL23R and IL17A [182–184]. IL-17 and IL-21 produced by
developing Th17 cells then mediate Th17 cell amplification, while IL-23 is particularly crucial for the
expansion and stabilization of Th17 cells, as well as their ability to induce tissue inflammation [182–185].
Exposure to IL-23 also reduces the concentration of anti-inflammatory IL-10 in developing Th17 cells, which
may further evoke a “pathogenic” profile in these cells (Figure 2) [182, 185]. In fact, IL-17-producing Th17
cells generated with TGF-β1 and IL-6 alone have been found to be incapable of inducing autoimmune disease
or producing “pathogenic” Th17 cells without further exposure to IL-23 [182, 185]. The key role of IL-23 is
further underlined by evidence that loss or inhibition of the IL-23-specific p19 subunit results in protection
from various autoimmune diseases, including experimental autoimmune encephalomyelitis and autoimmune
colitis, whereas loss of IL-17 or IL-17RA alone resulted in no protection or exacerbation of disease [184–186].

It is important to note that these Th17 cells are highly plastic and can be driven to become either
“non-pathogenic”, producing IL-10 and protective against pathogens, or “pathogenic”, producing IL-17 and
contributing to chronic inflammation [182, 185, 187]. As EMS patients have elevated levels of IL-17 compared
to healthy controls [180, 188], Th17 cells are likely “pathogenic” in EMS and a potential source of IL-17.
This is of interest due to the well-known pro-inflammatory and pro-angiogenic actions of IL-17 in chronic
inflammatory disorders and the pivotal role of this cytokine in the pathogenesis of EMS [135, 188, 189].
Furthermore, as levels of IL-23 have been found to be elevated in EMS [179, 190, 191], IL-23 is likely a key
contributor in driving Th17 cells to this pathogenic profile, producing IL-17 and exacerbating EMS [188].
However, the involvement of group 3 innate lymphoid cells (ILC3s) in this IL-23/IL-17 axis must also be
examined in the pathophysiology of EM, as IL-23 can similarly act on ILC3s to produce IL-17 [192, 193].

There is a critical balance between Th17 and Treg cells necessary to maintain immune homeostasis [194].
Disruptions in this ratio of Th17 and Treg cells have been well documented in EMS [133, 195–197]. Specifically,
patients with EMS have been found to have lower Treg cells (tolerant) and greater Th17 cells (inflammatory),
and this Th17 increase is associated with disease severity [133, 197]. This is of interest, if IL-23 is a key
contributor in driving Th17 cells to a pathogenic profile, IL-23 may then control the balance between Th17
and Treg cells which is critical to preventing chronic inflammation and autoimmunity [194, 198–200].

This evidence may call into question whether endometriosis should be investigated as an autoimmune
disorder. Indeed, some studies have found an association of endometriosis with autoimmune diseases, and
others have identified autoantibodies within endometriosis [201]. However, according to a systematic review
and meta-analysis by Shigesi et al. [202], out of 26 investigations, only 5 had good quality evidence, of which 4
reported an association of endometriosis with one or more autoimmune diseases.

**Immune-centered comorbidities may share common pathological mechanisms**
As we have discussed, the IL-23/Th17 axis is dysregulated in EMS, as well as various other chronic
inflammatory diseases, including psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple
sclerosis [185, 188, 200, 203, 204]. The clinical presentation of these diseases alongside EMS has been
extensively discussed [165, 202, 205–208]. Here, we will focus on the current gaps in the literature, particularly
on the possible pathophysiological pathways shared between EMS and its comorbidities in order to aid in the
discovery of novel therapeutic targets. The crucial role of the IL-23/Th17 axis in the pathogenesis of various
chronic inflammatory diseases has been confirmed using IL-23-specific p19 subunit inhibitors [209–211].
Currently, a few p19-specific IL-23 inhibitors have been Food and Drug Administration (FDA)-approved for
clinical use in the treatment of psoriasis and psoriatic arthritis, such as risankizumab, tildrakizumab, and
guselkumab, which are also currently in trial for other diseases with dysregulated IL-23/Th17 axis, such as
Crohn’s disease [209, 212–217].
Since the dysfunctionality of the IL-23/Th17 axis is a treatment target for the diseases comorbidly exhibited with EMS, it would also serve as a promising therapeutic target for EMS. Furthermore, as IL-23-driven Th17 cell differentiation is induced through Janus kinase (JAK)/STAT3 signaling, and this pathway is upregulated in EMS [218], this could provide an additional therapeutic target for EMS or any condition with dysregulated IL-23/Th17 axis. In fact, tofacitinib, a JAK inhibitor was tested on JAK/STAT signaling in an EMS mouse model and was found to result in EMS lesion regression and reduced adhesion burden as compared to controls [218]. This dysfunctional signaling pathway may be a potential therapeutic target for EMS comorbidities, such as psoriasis, as STAT3 has recently been shown to be a key player in the pathophysiology of psoriasis and psoriatic-like inflammatory conditions [219]. STAT3 has also been found to be positively correlated with rheumatoid arthritis and STAT3 loss was found to block joint inflammation in mouse models of arthritis [220–222]. This evidence suggests that both the IL-23/IL-17 axis and JAK/STAT3 signaling pathways may be viable therapeutic targets deserving further exploration in the treatment of EMS and related comorbidities (Figure 3).

**Figure 3.** Summarizing our perspectives on EMS therapeutic opportunities

The currently available options for EMS treatment are predominated by hormonal therapies, but many other opportunities exist to treat the immune dysregulation of EMS and target specific immune pathways. As EMS is a highly complex disease, treatment plans should move towards a personalized medicine approach, incorporating the individual’s hormonal and immunological profiles that can be captured through extracellular vesicle (EV) signatures.

**New advances in EMS diagnosis**

The current gold standard for diagnosis of EMS is diagnostic laparoscopy with inspection of the abdominal cavity and histological confirmation of suspected lesions. Considering the complex manifestations of EMS, obtaining the correct preoperative diagnosis is fundamental in defining the best treatment strategy. The World Endometriosis Research Foundation has agreed that one of the key research priorities for EMS is the development of reliable non-invasive tests [223]. However, in a systematic review, May et al. [224] evaluated over 100 biomarkers for EMS in serum, plasma, and urine, and could not identify any biomarker or diagnostic panel to recommend for clinical application. The heterogeneous nature of EMS poses a challenge in developing diagnostics capable of distinguishing different phenotypes and stages of EMS. Furthermore, the high incidence of comorbidities experienced by EMS patients create another challenge in finding diagnostic biomarkers; overlapping inflammatory and endocrine mechanisms of comorbid diseases can confound EMS...
signs and symptoms. Since surgery is invasive and expensive, other tests including imaging and biomarkers [glycoproteins, growth factors, microRNAs (miRNAs), and long noncoding RNAs (lncRNAs)] have been evaluated for their non-invasive diagnostic potential [225, 226].

**Immunological and exosomal biomarkers in endometriosis**

Immunological markers and inflammatory cytokines have been extensively studied in EMS patients, and despite an abundance of findings, no diagnostic value has been established. The most representative are IL-1, IL-6, IL-8, IFN-γ, MCP-1, and TNF-α [224]. Higher serum levels of IL-6 in EMS patients have been reported [227], though two systematic reviews could not verify a link between elevated serum levels of IL-6 and EMS due to testing parameters varying between studies [224, 228]. Several studies have shown higher levels of TNF-α in the serum of women with EMS [229–231], while others reported no difference [232, 233]. The concentration of IL-8 is reported to be increased in the PF of women with EMS [234] in correlation with disease stage severity [235]. As well, Carmona et al. [236] have reported that IL-8 is significantly higher in the serum of patients with ovarian endometrioma compared to healthy controls, but not in the serum of DIE patients. Several cytokines have been reported with higher serum values in earlier stages [232]. If ranges can be clearly defined, this could potentially help differentiate the EMS stage during diagnosis.

As discussed earlier, IL-17A and IL-23 are heavily involved in the pathogenesis of EMS and are found at significantly higher concentrations in the PF of EMS patients than in controls [188, 237, 238]. Furthermore, IL-17 along with TNF-α are involved in increasing IL-8 secretion [239]. As these cytokines have all been observed in higher levels in EMS patients’ serum or PF, and are all relevant to Th17-mediated inflammation, this axis is worth investigating further in terms of diagnostic panel design.

Other ILs have been studied in EMS, such as IL-4 which has been found to have higher serum values in adolescents with EMS [240]. As well, elevated serum IL-32 has been observed in EMS patients compared to controls [241]. Specifically, in cases of DIE, IL-33 has been found elevated in the serum and PF of patients versus healthy controls, with levels correlating to disease severity [242]. In peripheral blood, IL-8, MCP-1, and CCL5 showed potential as biomarkers, being significantly increased in EMS patients versus controls [48]. NK cells (CD57 + CD16) as potentially viable biomarkers have been reported to be lower in EMS and elevated one month after surgery to resect EMS lesions [243]. Interestingly, the expression of a killer inhibitory receptor known as killer inhibitory receptor 2 DL1 (KIR2DL1), on NK cells is reported to be higher in women with EMS [244]. This may explain why NK cells are less active in the disease, but more importantly, this discrepancy may be useful in identifying EMS. Copeptin, a molecule increased in inflammatory conditions, has been found significantly higher in EMS patient serum compared to controls and in correlation with disease stage severity [245]. In a study by Tuten et al. [246] the inflammatory biomarker glycoprotein YKL-40 was significantly elevated in patients with EMS compared to healthy controls, and positively correlated with disease severity. While several immunological biomarkers have been studied in EMS, many have failed repeatability tests. As well, most of these biomarkers are not EMS-specific enough to reliably diagnose EMS, given comorbid inflammatory diseases. For immunological biomarkers to be applicable in diagnostics, more research is required to define a unique panel of analytes.

In recent years, exosomes have emerged as a novel source of biomarkers in liquid biopsy has emerged with the potential to be used for early diagnostics and drug delivery-based therapeutics. Exosomes are a unique subset of EVs [247], at 30 nm to 150 nm in size they carry proteins, DNA, RNA, miRNA, and lncRNA [248]. These vesicles play an important role in the exchange of biological information between different cells; the incorporated genetic molecules can be taken up by neighboring or distant cells, where their contents enact downstream functions in recipient cells [248]. A study by Sun et al. [249] showed that exosomes isolated from the eutopic endometrium of a mouse model of EMS polarized macrophages into an M2-like phenotype and caused a reduction in their phagocytic ability, thereby enhancing the development of lesions. Furthermore, primary human endometrial stromal cell cultures from EMS patients were found to secrete exosomes with a unique proangiogenic miRNA profile, and these exosomes conferred proangiogenic (tubulogenic) properties to human umbilical vein endothelial cells (HUVECs) in culture [250]. The link between exosomes, immune
function, and angiogenesis in EMS is what makes exosomes an exciting route to explore in noninvasive biomarker research.

It has been reported that exosomes from ovarian endometrioma patients showed high levels of ecto-nucleotidases compared to simple ovarian cysts [251]. Ecto-nucleotidases regulate extracellular ATP and rising extracellular adenosine levels, contributing to the local immune suppression necessary for EMS progression [251]. Detecting ecto-nucleotidases in more accessible biological fluids would make them promising non-invasive EMS biomarkers [251]. Our group has demonstrated that EVs from EMS patient tissues and plasma samples carry unique signatures of miRNAs and lncRNAs [252]. Endometrial (epithelial and endothelial) cell cultures treated with patient and control plasma-derived EVs exhibited signatures of inflammatory and angiogenic cytokines involved in EMS progression [252]. miRNA-lncRNA proteomic signatures and networks inherent in EMS patient EVs have the potential to be used as biomarkers [252]. Further, Zhang et al. [253] showed that two exosomal miRNAs, miR-22-3p and miR-320a are significantly upregulated in the serum of EMS patients. The two miRNAs may play an important role in EMS occurrence and development and have the potential to be biomarkers for the diagnosis of EMS [253]. Recently it was reported that exosomes isolated from PF samples of 28 women at different stages of the disease showed specific proteins in the exosomes that were absent in the controls [254]. Five proteins were found exclusively in the EMS groups: peroxiredoxin 1 (PRDX1), histone H2A type 2-C, annexin A2 (ANXA2), inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), and the tubulin α-chain [254]. These proteins specifically found in EMS patient exosomes open up new avenues as biomarkers. It was illustrated in a study by Qiu et al. [255] that the exosomal antisense hypoxia-inducible factor (aHIF) is highly expressed in serum and endometriotic lesion tissue of EMS patients. This study also demonstrated that upon HUVECs internalizing exosomes from EMS cystic stromal cells, exosomal aHIF regulated angiogenesis-related genes, facilitating angiogenesis [255]. This highlights the potential clinical value of circulating exosomal aHIF as a biomarker. Overall, despite extensive efforts to find EMS biomarkers, no previous candidate has achieved the sensitivity and specificity required for a viable diagnostic tool. Exosomes show great promise as biomarkers and as novel drug delivery vehicles in cellular therapy (Figure 3). We must standardize the protocols and identification methods such that exosome biomarkers can be used in clinical settings.

Various phenotypes of EMS have distinct mechanisms, and as a result, a single distinctive biomarker is not feasible for all EMS cases. This is a central challenge to developing diagnostics, and further research is needed to identify a panel of biomarkers that accounts for the heterogeneous manifestations of EMS.

Conclusions and future perspectives
EMS is a highly complex, heterogeneous disorder that has multi-factorial etiology intertwined in genetic, hormonal, immune, and environmental predispositions. Recent evidences have uncovered the dynamic nature of the EMS lesion microenvironment with particular emphasis on immune-inflammatory changes and the evolving relationship between endocrine, immune, and pain aspects. While the general consensus in the literature is that EMS is a systemic disorder, further evidence is required to validate this notion. The puzzling question yet to be answered is whether the lesion microenvironment contributes to the inflammatory changes or arises as a response to the growing lesion. Analysis of inflammatory markers in PF and within the lesion itself can only provide a snapshot of the disease captured at the time of sample collection. However, we need to consider how long a patient has been harboring these lesions and associated chronic inflammation, hormonal imbalance, somatic mutations, or co-morbidities that might shape EMS lesion architecture. Another knowledge gap is the molecular/cellular underpinning of endometriotic lesion initiation and subsequent progression. Does immune dysfunction in an EMS patient facilitate lesion initiation? Studies focused on single-cell RNA sequencing within the lesion microenvironment will provide new context associated with the immune and non-immune basis of disease-specific pathways. It is important to keep in mind that the chronic nature of the disease combined with concurrent therapies to relieve lesion growth and pain further complicates the precise understanding of the pathophysiology of the disease.
There is growing consensus in the EMS research community that perhaps each EMS phenotype such as DIE, ovarian endometrioma, and peritoneal lesions have unique pathogenetic mechanisms, yet most studies lump EMS as one entity. Furthermore, associated comorbidities pose a significant challenge to understanding the pathophysiology of EMS. Another major consideration is the lack of suitable animal models that would mimic the spontaneous human disease scenario. Despite these challenges, research for the last decade in the EMS field has revealed new insights into disease pathogenesis via cell-cell communication through EVs, miRNAs, genome-wide association studies, etc. Going forward, the integration of new advances in genomics, proteomics, and lipidomics, combined with the generation of new experimental animal models including humanized mice will help pinpoint specific mechanisms contributing to EMS lesion growth and identify new diagnostic and therapeutic targets.

**Abbreviations**

- aHIF: antisense hypoxia-inducible factor
- BMDSCs: bone marrow-derived stem cells
- CCL: C-C motif chemokine ligand
- CD44: cluster of differentiation 44
- CPP: chronic pelvic pain
- CXCL: C-X-C motif chemokine ligand
- DIE: deep infiltrating endometriosis
- EMS: endometriosis
- ERβ: estrogen receptor β
- EV: extracellular vesicle
- GM-CSF: granulocyte-macrophage colony-stimulating factor
- IFN-γ: interferon-γ
- IL: interleukin
- JAK: Janus kinase
- IncRNAs: long noncoding RNAs
- MCP-1: monocyte chemoattractant protein-1
- MDSCs: myeloid-derived suppressor cells
- miRNAs: microRNAs
- MSCs: mesenchymal stem cells
- NGF: nerve growth factor
- NK: natural killer
- PD-1: programmed cell death 1
- PD-L1: programmed cell death-ligand 1
- PF: peritoneal fluid
- PRs: progesterone receptors
- STAT3: signal transducer and activator of transcription 3
- TGF-β: transforming growth factor beta
- Th: T helper
- TNF-α: tumor necrosis factor-alpha
- Treg: regulatory T
- VEGF: vascular endothelial growth factor
Declarations

Author contributions
AM conceived the main themes and subsections of the article. AM, DS, KZ, DH, KS, and SA reviewed and interpreted literature and wrote body of paper. AM, DS, KZ devised schematic figures. DS created illustrations. HL reviewed literature, advised on article design, and revised body of text. CT and MK advised on article design and direction and offered expertise on the article subject matter. CT oversaw the writing process and critically revised body of text.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical approval
Not applicable.

Consent to participate
Not applicable.

Consent to publication
Not applicable.

Availability of data and materials
Not applicable.

Funding
Not applicable.

Copyright
© The Author(s) 2022.

References
1. Levy AR, Osenenko KM, Lozano-Ortega G, Sambrook R, Jeddi M, Bélisle S, et al. Economic burden of surgically confirmed endometriosis in Canada. J Obstet Gynaecol Can. 2011;33:830–7.
2. Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol. 1980;137:327–31.
3. Hansen KA, Eyster KM. Genetics and genomics of endometriosis. Clin Obstet Gynecol. 2010;53:403–12.
4. Treloar SA, O’Connor DT, O’Connor VM, Martin NG. Genetic influences on endometriosis in an Australian twin sample. Fertil Steril. 1999;71:701–10.
5. Sapkota Y, Steinthorsdottir V, Morris AP, Fassbender A, Rahmioglu N, De Vivo I, et al.; iPSYCH-SSI-Broad Group, Yang J, Velez Edwards DR, Nyegaard M, Zondervan KT, Missmer SA, et al. Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. Nat Commun. 2017;8:15539.
6. Mear L, Herr M, Fauconnier A, Pineau C, Vialard F. Polymorphisms and endometriosis: a systematic review and meta-analyses. Hum Reprod Update. 2020;26:73–102.
7. Koninckx PR, Ussia A, Adamyen L, Wattiez A, Gomel V, Martin DC. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019;111:327–40.
8. Smolarz B, Szybko K, Romanowicz H. The genetic background of endometriosis: can ESR2 and CYP19A1 genes be a potential risk factor for its development? Int J Mol Sci. 2020;21:8235.
9. Yovich JL, Rowlands PK, Lingham S, Sillender M, Srinivasan S. Pathogenesis of endometriosis: look no further than John Sampson. Reprod Biomed Online. 2020;40:7–11.
10. Ferguson BR, Bennington JL, Haber SL. Histochemistry of mucosubstances and histology of mixed müllarian pelvic lymph node glandular inclusions. Evidence for histogenesis by müllarian metaplasia of coelomic epithelium. Obstet Gynecol. 1969;33:617–25.

11. Taguchi S, Enomoto Y, Homma Y. Bladder endometriosis developed after long-term estrogen therapy for prostate cancer. Int J Urol. 2012;19:964–5.

12. Laganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, et al. The pathogenesis of endometriosis: molecular and cell biology insights. Int J Mol Sci. 2019;20:5615.

13. Suginami H. A reappraisal of the coelomic metaplasia theory by reviewing endometriosis occurring in unusual sites and instances. Am J Obstet Gynecol. 1991;165:214–8.

14. Madding GF, Kennedy PA. Endometriosis: case supporting coelomic metaplasia as possible cause. JAMA. 1963;183:686–8.

15. Somigliana E, Infantino M, Candiani M, Vignali M, Chiodini A, Busacca M, et al. Association rate between deep peritoneal endometriosis and other forms of the disease: pathogenetic implications. Hum Reprod. 2004;19:168–71.

16. Batt RE, Yeh J. Müllerianosis: four developmental (embryonic) müllarian diseases. Reprod Sci. 2013;20:1030–7.

17. Lauchlan SC. The secondary Müllerian system. Obstet Gynecol Surv. 1972;27:133–46.

18. Marsh CA, Will MA, Smorgick N, Quint EH, Hussain H, Smith YR. Uterine remnants and pelvic pain in females with Mayer-Rokitansky-Küster-Hauser syndrome. J Pediatr Adolesc Gynecol. 2013;26:199–202.

19. Pitot MA, Bookwalter CA, Dudiak KM. Müllerian duct anomalies coincident with endometriosis: a review. Abdom Radiol (NY). 2020;45:1723–40.

20. Brosens I, Benagiano G. Is neonatal uterine bleeding involved in the pathogenesis of endometriosis as a source of stem cells? Fertil Steril. 2013;100:622–3.

21. Nirula R, Greaney GC. Incisional endometriosis: an underappreciated diagnosis in general surgery. J Am Coll Surg. 2000;190:404–7.

22. Zhang P, Sun Y, Zhang C, Yang Y, Zhang L, Wang N, et al. Cesarean scar endometriosis: presentation of 198 cases and literature review. BMC Womens Health. 2019;19:14.

23. Tanos V, Anteby SO. Cesarean scar endometriosis. Int J Gynaecol Obstet. 1994;47:163–6.

24. Ding DC, Hsu S. Scar endometriosis at the site of cesarean section. Taiwan J Obstet Gynecol. 2006;45:247–9.

25. Yıldırım D, Tatar C, Doğan O, Hut A, Dönmez T, Akıncı M, et al. Post-cesarean scar endometriosis. Turk J Obstet Gynecol. 2018;15:33–8.

26. Vellido-Cotelo R, Muñoz-González JL, Oliver-Pérez MR, de la Hera-Lázaro C, Almansa-González C, Pérez-Sagasta C, et al. Endometriosis node in gynaecologic scars: a study of 17 patients and the diagnostic considerations in clinical experience in tertiary care center. BMC Womens Health. 2015;15:13.

27. Wicherek L, Klimek M, Skret-Magierlo J, Czekierdowski A, Banas T, Popieła TJ, et al. The obstetrical history in patients with Pfannenstiel scar endometriomas— an analysis of 81 patients. Gynecol Obstet Invest. 2007;63:107–13.

28. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–69.

29. Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol. 1984;64:151–4.

30. D’Hooghe TM. Clinical relevance of the baboon as a model for the study of endometriosis. Fertil Steril. 1997;68:613–25.

31. D’Hooghe TM, Bambra CS, Suleman MA, Dunselman GA, Evers HL, Koninckx PR. Development of a model of retrograde menstruation in baboons (Papio anubis). Fertil Steril. 1994;62:635–8.
32. Nnoaham KE, Webster P, Kumbang J, Kennedy SH, Zondervan KT. Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies. Fertil Steril. 2012;98:702–12.e6.

33. Rutherford EJ, Hill ADK, Hopkins AM. Adhesion in physiological, benign and malignant proliferative states of the endometrium: microenvironment and the clinical big picture. Cells. 2018;7:43.

34. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18:177–200.

35. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Müller KH, Sharkey AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 1996;98:482–9.

36. Han SJ, Jung SY, Wu SP, Hawkins SM, Park MJ, Kyo S, et al. Estrogen receptor β modulates apoptosis complexes and the inflammaosome to drive the pathogenesis of endometriosis. Cell. 2015;163:960–74.

37. Sagaradze GD, Basalova NA, Efimenko AY, Tkachuk VA. Mesenchymal stromal cells as critical contributors to tissue regeneration. Front Cell Dev Biol. 2020;8:576176.

38. Kong Y, Shao Y, Ren C, Yang G. Endometrial stem/progenitor cells and their roles in immunity, clinical application, and endometriosis. Stem Cell Res Ther. 2021;12:474.

39. Du H, Naqvi H, Taylor HS. Ischemia/reperfusion injury promotes and granulocyte-colony stimulating factor inhibits migration of bone marrow-derived stem cells to endometrium. Stem Cells Dev. 2012;21:3324–31.

40. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369–77.

41. Leyendecker G, Herbertz M, Kunz G, Mall G. Endometriosis results from the dislocation of basal endometrium. Hum Reprod. 2002;17:2725–36.

42. Hapangama DK, Drury J, Da Silva L, Al-Lamee H, Earp A, Valentijn AJ, et al. Abnormally located SSEA1+/SOX9+ endometrial epithelial cells with a basalis-like phenotype in the eutopic functionalis layer may play a role in the pathogenesis of endometriosis. Hum Reprod. 2019;34:56–68.

43. Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40:1048–79.

44. Gellersen B, Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr Rev. 2014;35:851–905.

45. Ding Y, Song N, Luo Y. Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes. Cancer Microenviron. 2012;5:225–36.

46. Gagné D, Pagé M, Robitaille G, Hugo P, Gosselin D. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod. 2003;18:1674–80.

47. Suzumori N, Sugiura-Ogasawara M, Katano K, Suzumori K. Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas. Hum Reprod. 2003;18:2595–8.

48. Borrelli GM, Abrão MS, Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod. 2014;29:253–66.

49. Luz-Crawford P, Kurte M, Bravo-Alegria J, Contreras R, Nova-Lamperti E, Tejedor G, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013;4:65.

50. Thiruchelvam U, Wingfield M, O'Farrelly C. Natural killer cells: key players in endometriosis. Am J Reprod Immunol. 2015;74:291–301.
51. Cao X, Duan L, Hou H, Liu Y, Chen S, Zhang S, et al. IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGE2-mediated M2 macrophage polarization. Theranostics. 2020;10:7697–709.

52. François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20:187–95.

53. Giri J, Das R, Nylen E, Chinnadurai R, Galipeau J. CCL2 and CXCL12 derived from mesenchymal stromal cells cooperatively polarize IL-10+ tissue macrophages to mitigate gut injury. Cell Rep. 2020;30:1923–34.e4.

54. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell. 2012;11:812–24.

55. Abomaray F, Gidlöf S, Götherström C. Mesenchymal stromal cells are more immunosuppressive in vitro if they are derived from endometriotic lesions than from eutopic endometrium. Stem Cells Int. 2017;2017:3215962.

56. Mutlu L, Hufnagel D, Taylor HS. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol Reprod. 2015;92:138.

57. Sakr S, Naqvi H, Komm B, Taylor HS. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology. 2014;155:1489–97.

58. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–31.

59. Chen P, Mamillapalli R, Habata S, Taylor HS. Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling. Mol Cell Biochem. 2021;476:1717–27.

60. Wu L, Lv C, Su Y, Li C, Zhang H, Zhao X, et al. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol. 2019;35:251–6.

61. Virani S, Edwards AK, Thomas R, Childs T, Tayade C. Blocking of stromal cell-derived factor-1 reduces neoangiogenesis in human endometriosis lesions in a mouse model. Am J Reprod Immunol. 2013;70:386–97.

62. Moridi I, Mamillapalli R, Cosar E, Ersoy GS, Taylor HS. Bone marrow stem cell chemotactic activity is induced by elevated CXCL12 in endometriosis. Reprod Sci. 2017;24:526–33.

63. Zhang T, Zhou J, Man GCW, Leung KT, Liang B, Xiao B, et al. MDSCs drive the process of endometriosis by enhancing angiogenesis and provide a new potential therapeutic target. Eur J Immunol. 2018;48:1059–73.

64. Chen H, Qin S, Lei A, Li X, Gao Q, Dong J, et al. Expansion of monocytic myeloid-derived suppressor cells in endometriosis patients: a pilot study. Int Immunopharmacol. 2017;47:150–8.

65. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.

66. Zhu H, Gu Y, Xue Y, Yuan M, Cao X, Liu Q. CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. Oncotarget. 2017;8:114554–67.

67. Luan Y, Mosheir E, Menon MC, Wilson D, Woytovich C, Ochando J, et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4+ Foxp3+ Treg expansion. Am J Transplant. 2013;13:3123–31.

68. Suen JL, Chang Y, Chiu PR, Hsieh TH, Hsi E, Chen YC, et al. Serum level of IL-10 is increased in patients with endometriosis, and IL-10 promotes the growth of lesions in a murine model. Am J Pathol. 2014;184:464–71.
69. Tomić S, Joksimović B, Bekić M, Vasiljević M, Milanović M, Čolić M, et al. Prostaglandin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets. Front Immunol. 2019;10:475.

70. Millrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cells. Oncotarget. 2017;8:3649–65.

71. Guo P, Bi K, Lu Z, Wang K, Xu Y, Wu H, et al. CCR5/CCR5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis. Reprod Biomed Online. 2019;39:704–11.

72. Konrad L, Dietze R, Riaz MA, Scheiner-Bobis G, Behnke J, Horné F, et al. Epithelial–mesenchymal transition in endometriosis—when does it happen? J Clin Med. 2020;9:1915.

73. Jiang H, Bi K, Wang K, Lu Z, Xu Y, Guo P, et al. Reduction of myeloid derived suppressor cells by inhibiting Notch pathway prevents the progression of endometriosis in mice model. Int Immunopharmacol. 2020;82:106352.

74. Ngô C, Chéreau C, Nico C, Weill B, Chapron C, Batteux F. Reactive oxygen species controls endometriosis progression. Am J Pathol. 2009;175:225–34.

75. Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO, Faber TW, et al. Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J Leukoc Biol. 2014;95:643–50.

76. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, et al. Mast cells mobilize myeloid-derived suppressor cells and treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010;5:e8922.

77. Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol. 2019;10:2759.

78. Danelli L, Frossi B, Gri G, Mion F, Guarnotta C, Bongiovanni L, et al. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol Res. 2015;3:85–95.

79. Li T, Wang J, Guo X, Yu Q, Ding S, Xu X, et al. Possible involvement of crosstalk between endometrial cells and mast cells in the development of endometriosis via CCL8/CCR1. Biomed Pharmacother. 2020;129:110476.

80. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269–79.

81. Buggio L, Somigliana E, Barbara G, Frattaruolo MP, Vercellini P. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017;18:1569–81.

82. Farquhar C, Prentice A, Singla AA, Selak V. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2007;CD000068.

83. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–75.

84. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15:666–82.

85. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521–74.

86. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294:63–9.

87. Liang Y, Xie H, Wu J, Liu D, Yao S. Villainous role of estrogen in macrophage-nerve interaction in endometriosis. Reprod Biol Endocrinol. 2018;16:122.

88. Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I, Matsuyama T, et al. Estrogen and progesterone receptor expression in macrophages and regulation of hepatocyte growth factor by ovarian steroids in women with endometriosis. Hum Reprod. 2005;20:2004–13.
89. Arruvito L, Giulianielli S, Flores AC, Paladin N, Barboza M, Lanari C, et al. NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J Immunol. 2008;180:5746–53.

90. Wira CR, Fahey JV, Rodriguez-Garcia M, Shen Z, Patel MV. Regulation of mucosal immunity in the female reproductive tract: the role of sex hormones in immune protection against sexually transmitted pathogens. Am J Reprod Immunol. 2014;72:236–58.

91. Faas M, Bouman A, Moesa H, Heineman MJ, de Leij L, Schuling G. The immune response during the luteal phase of the ovarian cycle: a Th2-type response? Fertil Steril. 2000;74:1008–13.

92. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol. 2001;1:983–93.

93. Zierau O, Zenclussen AC, Jensen F. Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol. 2012;3:169.

94. Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, et al. Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol. 2008;196:67–77.

95. Zaitu M, Narita SI, Lambert KC, Grady JJ, Estes DM, Curran EM, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007;44:1977–85.

96. Watson CS, Norfleet AM, Pappas TC, Gametchu B. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids. 1999;64:5–13.

97. Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen-receptor expression and function in female reproductive disease. Cells. 2019;8:1123.

98. Yu J, Wang Y, Zhou WH, Wang L, He YY, Li DJ. Combination of estrogen and dioxin is involved in the pathogenesis of endometriosis by promoting chemokine secretion and invasion of endometrial stromal cells. Hum Reprod. 2008;23:1614–26.

99. Tsutsumi A, Okada H, Nakamoto T, Okamoto R, Yasuda K, Kanzaki H. Estrogen induces stromal cell-derived factor 1 (SDF-1/CXCL12) production in human endometrial stromal cells: a possible role of endometrial epithelial cell growth. Fertil Steril. 2011;95:444–7.

100. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19:406–18.

101. Huhtinen K, Desai R, Stähle M, Salminen A, Handelsman DJ, Perheentupa A, et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012;97:4228–35.

102. Delvoux B, Groothuis P, D’Hooghe T, Kyama C, Dunselman G, Romano A. Increased production of 17β-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab. 2009;94:876–83.

103. Oertelt-prigione S. Immunology and the menstrual cycle. Autoimmun Rev. 2012;11:A486–92.

104. Wira CR, Rodriguez-Garcia M, Patel MV. The role of sex hormones in immune protection of the female reproductive tract. Nat Rev Immunol. 2015;15:217–30.

105. Salamonsen LA, Lathbury LJ. Endometrial leukocytes and menstruation. Hum Reprod Update. 2000;6:16–27.

106. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85:2897–902.

107. Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum Reprod Update. 2019;25:473–85.

108. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248:94–103.

109. Bulun SE, Imir G, Utsunomiya H, Thung S, Gurutes B, Tamura M, et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005;95:57–62.
110. Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144:2870–81.

111. Yanagi K, Makinoda S, Fujii R, Miyazaki S, Fujita S, Tomizawa H, et al. Cyclic changes of granulocyte colony-stimulating factor (G-CSF) mRNA in the human follicle during the normal menstrual cycle and immunolocalization of G-CSF protein. Hum Reprod. 2002;17:3046–52.

112. Belot MP, Abdennabi-Najar L, Gaudin F, Lieberherr M, Godot V, Taieb J, et al. Progesterone reduces the migration of mast cells toward the chemokine stromal cell-derived factor-1/CXCL12 with an accompanying decrease in CXCR4 receptors. Am J Physiol Endocrinol Metab. 2007;292:E1410–7.

113. Vasiadi M, Kempuraj D, Boucher W, Kalogeronitmos D, Theoharides TC. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol. 2006;19:787–94.

114. Jezierska M, Salamonsen LA, Woolley DE. Mast cell and eosinophil distribution and activation in human endometrium throughout the menstrual cycle. Biol Reprod. 1995;53:312–20.

115. De Leo B, Esnal-Zuñiraure A, Collins F, Critchley HOD, Saunders PTK. Immunoprofiling of human uterine mast cells identifies three phenotypes and expression of ERβ and glucocorticoid receptor. F1000Res. 2017;6:667.

116. Sugamata M, Ibara T, Uchiide I. Increase of activated mast cells in human endometriosis. Am J Reprod Immunol. 2005;53:120–5.

117. Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noël JC. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril. 2006;86:1336–43.

118. Osuga Y, Koga K, Tsutsumi O, Igarashi T, Okagaki R, Takai Y, et al. Stem cell factor (SCF) concentrations in peritoneal fluid of women with or without endometriosis. Am J Reprod Immunol. 2000;44:231–5.

119. Berbic M, Schulte L, Markham R, Tokushige N, Russell P, Fraser IS. Macrophage expression in endometrium of women with and without endometriosis. Hum Reprod. 2009;24:325–32.

120. Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I, Ishimaru T. Differential macrophage infiltration in early and advanced endometriosis and adjacent peritoneum. Fertil Steril. 2004;81:652–61.

121. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.

122. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–92.

123. Wang Y, Chen H, Wang N, Guo H, Fu Y, Xue S, et al. Combined 17β-estradiol with TCDD promotes M2 polarization of macrophages in the endometriotic milieu with aid of the interaction between endometrial stromal cells and macrophages. PLoS One. 2015;10:e0125559.

124. Campbell L, Emmerson E, Williams H, Saville CR, Krust A, Chambon P, et al. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J Invest Dermatol. 2014;134:2447–57.

125. Keselman A, Fang X, White PB, Heller NM. Estrogen signaling contributes to sex differences in macrophage polarization during asthma. J Immunol. 2017;199:1573–83.

126. Bonatz G, Hansmann ML, Buchholz F, Mettler L, Radzun HJ, Semm K. Macrophage- and lymphocyte-subtypes in the endometrium during different phases of the ovarian cycle. Int J Gynaecol Obstet. 1992;37:29–36.

127. Jing X, Peng J, Dou Y, Sun J, Ma C, Wang Q, et al. Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition. Immunol Cell Biol. 2019;97:563–76.

128. Montagna P, Capellino S, Villaggio B, Remorgida V, Ragni N, Cutolo M, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril. 2008;90:156–64.
129. Cutolo M, Capellino S, Montagna P, Ghiorzo P, Sulli A, Villaggio B. Sex hormone modulation of cell growth and apoptosis of the human monocyctic/macrophage cell line. Arthritis Res Ther. 2005;7:R1124–32.

130. Hogg C, Horne AW, Greaves E. Endometriosis-associated macrophages: origin, phenotype, and function. Front Endocrinol (Lausanne). 2020;11:7.

131. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol. 2007;19:337–43.

132. Mohammad I, Starskaia I, Nagy T, Guo J, Yatkin E, Väänänen K, et al. Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation. Sci Signal. 2018;11:eaap9415.

133. Gogacz M, Winkler I, Bojarska-Junak A, Tabarkiewicz J, Semczuk A, Rechberger T, et al. Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis. J Reprod Immunol. 2016;117:39–44.

134. Fuseini H, Cephus JY, Wu P, Davis JB, Contreras DC, Gandhi VD, et al. ERα signaling increased IL-17A production in Th17 cells by upregulating IL-23R expression, mitochondrial respiration, and proliferation. Front Immunol. 2019;10:2740.

135. Miller JE, Ahn SH, Marks RM, Monsanto SP, Fazleabas AT, Koti M, et al. IL-17A modulates peritoneal macrophage recruitment and M2 polarization in endometriosis. Front Immunol. 2020;11:108.

136. Che Q, Liu BY, Liao Y, Zhang HJ, Yang TT, He YY, et al. Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17β-estradiol biosynthesis in endometrial carcinoma microenvironment. Int J Cancer. 2014;135:282–94.

137. Velasco I, Acín P, Campos A, Acién MI, Ruiz-Maciá E. Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. J Reprod Immunol. 2010;84:199–205.

138. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995;80:3052–8.

139. Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, et al. Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell. 2017;65:1122–35.e5.

140. Guo SW. Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology. Hum Reprod Update. 2020;26:423–49.

141. Montgomery GW, Mortlock S, Giudice LC. Should genetics now be considered the pre-eminent etiologic factor in endometriosis? J Minim Invasive Gynecol. 2020;27:280–6.

142. Li X, Zhang Y, Zhao L, Wang L, Wu Z, Mei Q, et al. Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. Hum Mol Genet. 2014;23:6008–21.

143. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376:1835–48.

144. Lac V, Verhoef L, Aguirre-Hernandez R, Nazeran TM, Tessier-Cloutier B, Praetorius T, et al. Iatrogenic endometriosis harbors somatic cancer-driver mutations. Hum Reprod. 2019;34:69–78.

145. Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori Y, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777–89.

146. Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679.

147. Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, et al. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer. 2018;121:70–5.
148. Kato T, Park JH, Kiyotani K, Ikeda Y, Miyoshi Y, Nakamura Y. Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget. 2017;8:62029–38.

149. Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology. 2017;6:e1278330.

150. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7.

151. Du L, Chen X, Cao Y, Lu L, Zhang F, Bornstein S, et al. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling. Oncogene. 2016;35:4641–52.

152. Guo M, Bafligil C, Tapmeier T, Hubbard C, Manek S, Shang C, et al. Mass cytometry analysis reveals a distinct immune environment in peritoneal fluid in endometriosis: a characterisation study. BMC Med. 2020;18:3.

153. Vallvé-Juanico J, Houshdaran S, Giudice LC. The endometrial immune environment of women with endometriosis. Hum Reprod Update. 2019;25:565–92.

154. Lac V, Huntsman DG. Distinct developmental trajectories of endometriothelial epithelium and stroma: implications for the origins of endometriosis. J Pathol. 2018;246:257–60.

155. Noë M, Ayhan A, Wang TL, Shih IM. Independent development of endometriothelial epithelium and stroma within the same endometriosis. J Pathol. 2018;245:265–9.

156. Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Adachi S, Kase H, et al. Different mutation profiles between epithelium and stroma in endometriosis and normal endometrium. Hum Reprod. 2019;34:1899–905.

157. Bulun SE, Wan Y, Matei D. Epithelial mutations in endometriosis: link to ovarian cancer. Endocrinology. 2019;160:626–38.

158. Lac V, Nazeran TM, Tessier-Cloutier B, Aguirre-Hernandez R, Albert A, Lum A, et al. Oncogenic mutations in histologically normal endometrium: the new normal? J Pathol. 2019;249:173–81.

159. Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun. 2021;12:1808.

160. Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review. Oncotarget. 2017;8:48248–52.

161. Bloks T, Pierson R. Endometriosis and chronic pelvic pain: unraveling the mystery behind this complex condition. Nurs Womens Health. 2008;12:382–95.

162. Lamvu G, Carrillo J, Ouyang C, Rapkin A. Chronic pelvic pain in women: a review. JAMA. 2021;325:2381–91.

163. Maddern J, Grundy L, Castro J, Brierley SM. Pain in endometriosis. Front Cell Neurosci. 2020;14:590823.

164. Phan VT, Stratton P, Tandon HK, Sinaii N, Aredo JV, Karp BI, et al. Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: a cross-sectional study. Eur J Pain. 2021;25:831–40.

165. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4:9.

166. Brooks AM, Ottley KM, Arbuthnott KD, Sevigny P. Nature-related mood effects: season and type of nature contact. J Environ Psychol. 2017;54:91–102.

167. Warzecha D, Szymbuski I, Wielgos M, Pietrzak B. The impact of endometriosis on the quality of life and the incidence of depression—a cohort study. Int J Environ Res Public Health. 2020;17:3641.

168. Dydyk AM, Gupta N. Chronic Pelvic Pain. Treasure Island (FL): StatPearls Publishing; 2022.

169. Breser ML, Salazar FC, Rivero VE, Motrich RD. Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome. Front Immunol. 2017;8:898.
170. Murphy SF, Schaeffer AJ, Thumbikat P. Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol. 2014;11:259–69.

171. Machairiotis N, Vasilakaki S, Thomakos N. Inflammatory mediators and pain in endometriosis: a systematic review. Biomedicines. 2021;9:54.

172. Vermeulen W, De Man JG, Pelckmans PA, De Winter BY. Neuroanatomy of lower gastrointestinal pain disorders. World J Gastroenterol. 2014;20:1005–20.

173. Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, et al. Immunological basis of the endometriosis: the complement system as a potential therapeutic target. Front Immunol. 2021;11:599117.

174. Saunders PTK, Horne AW. Endometriosis: etiology, pathobiology, and therapeutic prospects. Cell. 2021;184:2807–24.

175. Peng B, Alotaibi FT, Sediqi S, Bedaiwy MA, Yong PJ. Role of interleukin-1β in nerve growth factor expression, neurogenesis and deep dyspareunia in endometriosis. Hum Reprod. 2020;35:901–12.

176. Evans SF, Kwok YH, Solterbeck A, Liu J, Hutchinson MR, Hull ML, et al. Toll-like receptor responsiveness of peripheral blood mononuclear cells in young women with dysmenorrhea. J Pain Res. 2020;13:503–16.

177. Till SR, As-Sanie S, Schrepf A. Psychology of chronic pelvic pain: prevalence, neurobiological vulnerabilities, and treatment. Clin Obstet Gynecol. 2019;62:22–36.

178. Passavanti MB, Pota V, Sansone P, Aurilio C, De Nardis L, Pace MC. Chronic pelvic pain: assessment, evaluation, and objectivation. Pain Res Treat. 2017;2017:9472925.

179. Tarokh M, Ghaffari Novin M, Poordast T, Tavana Z, Nazarian H, Norouzian M, et al. Serum and periuteal fluid cytokine profiles in infertile women with endometriosis. Iran J Immunol. 2019;16:151–62.

180. Sikora J, Smycz-Kubańska M, Mienczarek-Palacz A, Bednarek I, Kondera-Anasz Z. The involvement of multifunctional TGF-β and related cytokines in pathogenesis of endometriosis. Immunol Lett. 2018;201:31–7.

181. Sachedin A, Todd N. Dysmenorrhea, endometriosis and chronic pelvic pain in adolescents. J Clin Res Pediatr Endocrinol. 2020;12:7–17.

182. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012;13:991–9.

183. Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719–29.

184. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43:1040–51.

185. Wu X, Tian J, Wang S. Insight into non-pathogenic Th17 cells in autoimmune diseases. Front Immunol. 2018;9:1112.

186. Wang R, Hasnain SZ, Tong H, Das I, Che-Hao Chen A, Oancea I, et al. Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis model. Inflamm Bowel Dis. 2015;21:973–84.

187. Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A. 2015;112:7061–6.

188. Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA, Tayade C. IL-17A contributes to the pathogenesis of endometriosis by triggering proinflammatory cytokines and angiogenic growth factors. J Immunol. 2015;195:2591–600.

189. Saito S, Nakashima A, Ito M, Shima T. Clinical implication of recent advances in our understanding of IL-17 and reproductive immunology. Expert Rev Clin Immunol. 2011;7:649–57.

190. Malvezzi H, Hernandez C, Piccinato CA, Podgaec S. Interleukin in endometriosis-associated infertility-pelvic pain: systematic review and meta-analysis. Reproduction. 2019;158:1–12.
191. Zhang QF, Chen GY, Liu Y, Huang HJ, Song YF. Relationship between resistin and IL-23 levels in follicular fluid in infertile patients with endometriosis undergoing IVF-ET. Adv Clin Exp Med. 2017;26:1431–5.

192. Geremia A, Arancibia-Cárcao CV, Fleming MPP, Rust N, Singh B, Mortensen NJ, et al. IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–33.

193. Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F. ILCl3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis. 2019;10:315.

194. Lee GR. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 2018;19:730.

195. Pashizheh F, Mansouri R, Davari-Tanha F, Hosseini R, Asgari Z, Aghaei H, et al. Alterations of CD4+T cell subsets in blood and peritoneal fluid in different stages of endometriosis. Int J Fertil Steril. 2020;14:201–8.

196. Cho YJ, Lee SH, Park JW, Han M, Park MJ, Han SJ. Dysfunctional signaling underlying endometriosis: current state of knowledge. J Mol Endocrinol. 2018;60:R97–113.

197. Le NXH, Loret de Mola JR, Bremer P, Groesch K, Wilson T, Diaz-Sylvestre P, et al. Alteration of systemic and uterine endometrial immune populations in patients with endometriosis. Am J Reprod Immunol. 2021;85:e13362.

198. Khan KN, Yamamoto K, Fujishita A, Muto H, Koshiba A, Kuroboshi H, et al. Differential levels of regulatory T cells and Th17 cells in women with early and advanced endometriosis. J Clin Endocrinol Metab. 2019;104:4715–29.

199. Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol. 2008;1:339–49.

200. Astry B, Venkatesha SH, Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. Cytokine. 2015;74:54–61.

201. Greenbaum H, Galper BEL, Decter DH, Eisenberg VH. Endometriosis and autoimmunity: can autoantibodies be used as a non-invasive early diagnostic tool? Autoimmun Rev. 2021;20:102795.

202. Shigesi N, Kvaksmoff M, Kirtley S, Feng Q, Fang H, Knight JC, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019;25:486–503.

203. Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford). 2018;57:246–54.

204. Lord JD. Promises and paradoxes of regulatory T cells in inflammatory bowel disease. World J Gastroenterol. 2015;21:11236–45.

205. Xue YH, You LT, Ting HF, Chen YW, Sheng ZY, Xie YD, et al. Increased risk of rheumatoid arthritis among patients with endometriosis: a nationwide population-based cohort study. Rheumatology (Oxford). 2021;60:3326–33.

206. Schink M, Konturek PC, Herbert SL, Renner SP, Burghaus S, Blum S, et al. Different nutrient intake and prevalence of gastrointestinal comorbidities in women with endometriosis. J Physiol Pharmacol. 2019;70:255–68.

207. Peng YH, Su SY, Liao WC, Huang CW, Hsu CY, Chen HJ, et al. Asthma is associated with endometriosis: a retrospective population-based cohort study. Respir Med. 2017;132:112–6.

208. Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017;209:3–7.

209. Torres T. Selective IL-23 inhibitors: the new kids on the block in the treatment of psoriasis. Actas Dermosifiliogr (Engl Ed). 2018;109:674–6.

210. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605–13.
211. Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.

212. Serrano L, Maloney V, Gordon KB. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019;11:1357–70.

213. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2021;17:5–13.

214. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother. 2020;54:380–7.

215. Visvanathan S, Baum P, Salas A, Vinisko R, Grebe KM, et al. Selective IL-23 inhibition by risankizumabmodulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: results from a randomised phase II biopsy sub-study. J Crohns Colitis. 2018;12:1170–9.

216. Feagan BG, Panés J, Ferrante M, Kaser A, D’Haens GR, Sandborn WJ, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3:671–80.

217. Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, et al. Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: results from the phase 2 open-label extension study. J Crohns Colitis. 2021;15:2001–10.

218. Kotlyar AM, Mamillapalli R, Flores VA, Taylor HS. Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression. Mol Hum Reprod. 2021;27:gaab016.

219. Calautti E, Avalle L, Poli V. Psoriasis: a STAT3-centric view. Int J Mol Sci. 2018;19:171.

220. Oike T, Sato Y, Kobayashi T, Miyamoto K, Nakamura S, Kaneko Y, et al. Stat3 as a potential therapeutic target for rheumatoid arthritis. Sci Rep. 2017;7:10965.

221. Chang L, Feng X, Gao W. Proliferation of rheumatoid arthritis fibroblast-like synoviocytes is enhanced by IL-17-mediated autophagy through STAT3 activation. Connect Tissue Res. 2019;60:358–66.

222. Paradowska-Gorycka A, Wajda A, Romanowska-Próchnicka K, Walczuk E, Kuca-Warnawin E, Kniolek T, et al. Th17/Treg-related transcriptional factor expression and cytokine profile in patients with rheumatoid arthritis. Front Immunol. 2020;11:572858.

223. Rogers PAW, D’Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, Petraglia F, et al. Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci. 2013;20:483–99.

224. May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update. 2010;16:651–74.

225. Kiesel L, Sourouni M. Diagnosis of endometriosis in the 21st century. Climacteric. 2019;22:296–302.

226. Fassbender A, Burney RO, O DF, D’Hooghe T, Giudice L. Update on biomarkers for the detection of endometriosis. Biomed Res Int. 2015;2015:130854.

227. Martínez S, Garrido N, Coperias JL, Pardo F, Desco J, García-Velasco JA, et al. Serum interleukin-6 levels are elevated in women with minimal–mild endometriosis. Hum Reprod. 2007;22:836–42.

228. Nisenblat V, Bossuyt PMM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;2016:CD012179.

229. Xavier P, Belo L, Beires J, Rebeiro I, Martínez-de-Oliveira J, Lunet N, et al. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet. 2006;273:227–31.

230. Cho SH, Oh YJ, Nam A, Kim HY, Park JH, Kim JH, et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. Am J Reprod Immunol. 2007;58:497–504.

231. Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod. 2002;17:426–31.
232. Othman EEDR, Hornung D, Salem HT, Khalifa EA, El-Metwally TH, Al-Hendy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2008;137:240–6.

233. Seeber B, Sammel MD, Fan X, Gerton GL, Shaunik A, Chittams J, et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertil Steril. 2008;89:1073–81.

234. Iwabe T, Harada T, Tsudo T, Tanikawa M, Onohara Y, Terakawa N. Pathogenetic significance of increased levels of interleukin-8 in the peritoneal fluid of patients with endometriosis. Fertil Steril. 1998;69:924–30.

235. Calhaz-Jorge C, Costa AP, Santos MC, Palma-Carlos ML. Peritoneal fluid concentrations of interleukin-8 in patients with endometriosis depend on the severity of the disorder and are higher in the luteal phase. Hum Reprod. 2003;18:593–7.

236. Carmona F, Chapron C, Martînez-Zamora MÁ, Santulli P, Rabanal A, Martînez-Florena M, et al. Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. J Reprod Immunol. 2012;95:80–6.

237. Zhang X, Xu H, Lin J, Qian Y, Deng L. Peritoneal fluid concentrations of interleukin-17 correlate with the severity of endometriosis and infertility of this disorder. BJOG. 2005;112:1153–5.

238. Andreoli CG, Genro VK, Souza CA, Michelon T, Bilibio JP, Scheffel C, et al. T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertil Steril. 2011;95:2477–80.

239. Honda K, Wada H, Nakamura M, Nakamoto K, Inui T, Sada M, et al. IL-17A synergistically stimulates TNF-α-induced IL-8 production in human airway epithelial cells: a potential role in amplifying airway inflammation. Exp Lung Res. 2016;42:205–16.

240. Drosdzol-Cop A, Skrzypulec-Plinta V, Stojko R. Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstet Gynecol Surv. 2012;67:374–81.

241. Choi YS, Kim S, Oh YS, Cho S, Hoon Kim S. Elevated serum interleukin-32 levels in patients with endometriosis: a cross-sectional study. Am J Reprod Immunol. 2019;82:e13149.

242. Santulli P, Borghese B, Chouzenoux S, Vaiman D, Borderie D, Streuli I, et al. Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis. Hum Reprod. 2012;27:2001–9.

243. Kikuchi Y, Ishikawa N, Hirata J, Imaizumi E, Sasa H, Nagata I. Changes of peripheral blood lymphocyte subsets before and after operation of patients with endometriosis. Acta Obstet Gynecol Scand. 1993;72:157–61.

244. Maeda N, Izumiya C, Oguri H, Kusume T, Yamamoto Y, Fukaya T. Aberrant expression of intercellular adhesion molecule-1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis. Fertil Steril. 2002;77:679–83.

245. Tuten A, Kucur M, Imamoglu M, Kaya B, Acikgoz AS, Yilmaz N, et al. Copeptin is associated with the severity of endometriosis. Arch Gynecol Obstet. 2014;290:75–82.

246. Tuten A, Kucur M, Imamoglu M, Oncul M, Acikgoz AS, Sofiyeva N, et al. Serum YKL-40 levels are altered in endometriosis. Gynecol Endocrinol. 2014;30:381–4.

247. Goričar K, Dolžan V, Lenassi M. Extracellular vesicles: a novel tool facilitating personalized medicine and pharmacogenomics in oncology. Front Pharmacol. 2021;12:671298.

248. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347–57.

249. Sun H, Li D, Yuan M, Li Q, Zhen Q, Li N, et al. Macrophages alternatively activated by endometriosis-exosomes contribute to the development of lesions in mice. Mol Hum Reprod. 2019;25:5–16.

250. Harp D, Driss A, Mehrabi S, Chowdhury I, Xu W, Liu D, et al. Exosomes derived from endometriotic stromal cells have enhanced angiogenic effects in vitro. Cell Tissue Res. 2016;365:187–96.
251. Texidó L, Romero C, Vidal A, García-Valero J, Fernández Montoli ME, Baixeras N, et al. Ecto-nucleotidases activities in the contents of ovarian endometriomas: potential biomarkers of endometriosis. Mediators Inflamm. 2014;2014:120673.

252. Khalaj K, Miller JE, Lingegowda H, Fazleabas AT, Young SL, Lessey BA, et al. Extracellular vesicles from endometriosis patients are characterized by a unique miRNA-IncRNA signature. JCI Insight. 2019;4:e128846.

253. Zhang L, Li H, Yuan M, Li D, Sun C, Wang G. Serum exosomal microRNAs as potential circulating biomarkers for endometriosis. Dis Markers. 2020;2020:2456340.

254. Nazri HM, Imran M, Fischer R, Heilig R, Manek S, Dragovic RA, et al. Characterization of exosomes in peritoneal fluid of endometriosis patients. Fertil Steril. 2020;113:364–73.e2.

255. Qiu JJ, Lin XJ, Zheng TT, Tang XY, Zhang Y, Hua KQ. The exosomal long noncoding RNA aHIF is upregulated in serum from patients with endometriosis and promotes angiogenesis in endometriosis. Reprod Sci. 2019;26:1590–602.